Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06087718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Feasibility of the Maastro Applicator in Rectal Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 14, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jul 2024 to Aug 27, 2024v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2024 to Aug 27, 2024
  2. Primary completion date: Sep 2025 to Apr 2026 Start date: Dec 2023 to Jul 2024 · Completion date: Sep 2030 to Apr 2031 · Secondary endpoints: details revised at 1 of 18 entriesv2 Show 3 more changesShow less
    • Start date: Dec 2023 to Jul 2024
    • Completion date: Sep 2030 to Apr 2031
    • Secondary endpoints: details revised at 1 of 18 entries
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.
Trial Details
NCT Number NCT06087718
Lead Sponsor Maastricht Radiation Oncology
Collaborators: Varian Medical Systems
Conditions Rectal Cancer, Feasibility, Toxicity, Quality of Life, Radiation Toxicity, Radiation Proctitis, Brachytherapy, Complete Response
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov